topic

536 EZH2 senses metabolic stress to restore MHC-I antigen presentation and ICB response in metastatic melanoma
Jacob L Edmondson, Megan R Reed, Daniel Fil, Billie Heflin, Alan J Tackett, Brian Koss

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A610; DOI: 10.1136/jitc-2023-SITC2023.0536
537 PPARG amplification is associated with lack of response to anti-PD1 in muscle-invasive urothelial cancer
Evisa Gjini, Stefan Kirov, Michaela Bowden

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A611; DOI: 10.1136/jitc-2023-SITC2023.0537
538 Longitudinal transcriptomic local and peripheral changes are associated with immunotherapy resistance in murine model of triple negative breast cancer
Ann Hanna, Xiaopeng Sun, Quanhu Sheng, Paula Gonzalez Ericsson, Emily N Tran, Susan Opalenik, Justin M Balko

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A612; DOI: 10.1136/jitc-2023-SITC2023.0538
539 Depletion of soluble PD-L1 with engineered NaNot^® nanoparticles promotes antitumor immunity
Michelle Hsu, Jacob Hirdler, Roxane Lavoie, Kevin Pavelko, Jacob Orme, Xin Liu, Lou Hawthorne, Curtis Ruegg, John Dodgson, Sean Park, Haidong Dong, Fabrice Lucien-Matteoni

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A613; DOI: 10.1136/jitc-2023-SITC2023.0539
540 A novel antibody that induces PD-L1 degradation results in enhanced tumor responses in a humanized PD-L1 breast carcinoma mouse model compared to Atezolizumab
Michelle Hsu, Xin Liu, Whitney Barham, Sue Harrington, Fabrice Lucien-Matteoni, Haidong Dong

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A614; DOI: 10.1136/jitc-2023-SITC2023.0540
541 Diabetes and glucose level as metabolic determinants of immune checkpoint inhibitors response in melanoma
Yu Jen A Jan, Soravis Osataphan, Cho Han Chiang, Kerry Reynolds, Ryan Sullivan

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A615; DOI: 10.1136/jitc-2023-SITC2023.0541
542 TIGIT as a potential therapeutic target in renal cell carcinoma
Soki Kashima, Hanna Soulati, Katrine Madsen, Katherine Sadak, Lena Wirth, Michael Hurwitz, Harriet Kluger, Mario Sznol, Peter Humphrey, Adebowale Adeniran, Patrick Kenney, David Braun

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A616; DOI: 10.1136/jitc-2023-SITC2023.0542
543 Cis-binding/blockade of CD47 by CD47xPD1 BsAb HX009 enhanced PD1 blockade induced T-cell activation
Hang Ke, Cen Chen, Faming Zhang, Henry Li

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A617; DOI: 10.1136/jitc-2023-SITC2023.0543
544 Coordinated blockade of TGF-β and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector memory responses
Jacob LK Kment, Daniel Newsted, Stephanie Young, Michael Vermeulen, Andrew W Craig

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A618; DOI: 10.1136/jitc-2023-SITC2023.0544
545 ATX/LPA upregulation via microRNA-29 loss suppresses cytotoxic T cells and promotes resistance to anti-PD-1 in non-small cell lung cancer
Jessica M Konen, B Leticia Rodriguez, Haoyi Wu, Jared Fradette, Laura Gibson, Lixia Diao, Jing Wang, Stephanie Schmidt, Ignacio Wistuba, Jianjun Zhang, Don Gibbons

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A619; DOI: 10.1136/jitc-2023-SITC2023.0545

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages